Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H22N6O3S |
| Molecular Weight | 402.471 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC=C(NC2=NC(OCC3CCCCC3)=C4NC=NC4=N2)C=C1
InChI
InChIKey=OWXORKPNCHJYOF-UHFFFAOYSA-N
InChI=1S/C18H22N6O3S/c19-28(25,26)14-8-6-13(7-9-14)22-18-23-16-15(20-11-21-16)17(24-18)27-10-12-4-2-1-3-5-12/h6-9,11-12H,1-5,10H2,(H2,19,25,26)(H2,20,21,22,23,24)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19426695 | https://www.ncbi.nlm.nih.gov/pubmed/12244298Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21570822
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19426695 | https://www.ncbi.nlm.nih.gov/pubmed/12244298
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21570822
NU6102 is a potent CDK1/cyclin B and CDK2/cyclin A3 inhibitor (IC50 values are 9.5 and 5.4 nM for CDK1/cyclin B and CDK2/cyclin A3 respectively). Antiproliferative agent. Induces G2/M cell cycle arrest. Shows antitumor effects in vivo. NU6102 and its prodrug NU6301 have pharmacological properties consistent with CDK2 inhibition, and represent useful tool molecules for the evaluation of CDK2 as a target in cancer.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. | 2011-09 |
|
| The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2. | 2009-05-15 |
|
| Study of a ligand complexed with Cdk2/Cdk4 by computer simulation. | 2005-11 |
|
| Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. | 2002-10 |
Patents
Sample Use Guides
Mice: Mice were
treated with either the maximum administrable dose of
NU6102 i.p. (10 mg/kg in a vehicle of 40% (v/v) polyethylene
glycol400) or i.v. (1 mg/kg i.v. in a vehicle of 10% (v/v) polyethylene
glycol400), or a dose of 10 mg/kg NU6301, equivalent to 8.4 mg/kg NU6102, in sterile saline for both i.v. and i.p.
administration.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID70274438
Created by
admin on Mon Mar 31 22:56:27 GMT 2025 , Edited by admin on Mon Mar 31 22:56:27 GMT 2025
|
PRIMARY | |||
|
X5J53DR704
Created by
admin on Mon Mar 31 22:56:27 GMT 2025 , Edited by admin on Mon Mar 31 22:56:27 GMT 2025
|
PRIMARY | |||
|
4566
Created by
admin on Mon Mar 31 22:56:27 GMT 2025 , Edited by admin on Mon Mar 31 22:56:27 GMT 2025
|
PRIMARY | |||
|
444722-95-6
Created by
admin on Mon Mar 31 22:56:27 GMT 2025 , Edited by admin on Mon Mar 31 22:56:27 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
